In vitro activity of eight oral cephalosporins against Borrelia burgdorferi

International Journal of Antimicrobial Agents

Volumn 21, Issue 4, 2003, Pages 313-318

  Hunfeld, Klaus Peter ^a   Rödel, Rebecca ^a   Wichelhaus, Thomas A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Borrelia burgdorferi; Cephalosporins; Minimal inhibitory concentration, in vitro susceptibility

Indexed keywords

APRAMYCIN; CEFACLOR; CEFDINIR; CEFETAMET PIVOXIL; CEFIXIME; CEFPODOXIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; LORACARBEF;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BORRELIA BISSETTII; BORRELIA BURGDORFERI; BORRELIA INFECTION; BORRELIA VALAISIANA; CULTURE MEDIUM; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; IN VITRO STUDY; INCUBATION TIME; INOCULATION; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPIROCHETE; TICK;

EID: 0037382986     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00005-0     Document Type: Article

References (22)

1. Steere A. Lyme disease. N. Engl. J. Med. 345:2001;115-125.
2. Wormser G.P., Nadelman R.B., Dattwyler R.J., et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin. Infect. Dis. 31:(Suppl 1):2000;1-14.
3. Nowakowski J., McKenna D., Nadelman R.B., et al. Failure of treatment with cephalexin for Lyme disease. Arch. Fam. Med. 9:2000;563-567.
4. Agger W.A., Callister S.M., Jobe D.A. In vitro susceptibilities of B. burgdorferi to 5 oral cephalosporins and ceftriaxone. Antimicrob. Agents Chemother. 36:1992;1788-1790.
5. Hunfeld K.P., Wichelhaus T.A., Kekoukh E., Molitor M., Kraiczy P., Brade V. In vitro susceptibility of the B. burgdorferi sensu lato complex to ABT-773, a novel ketolide. J. Antimicrob. Chemother. 48:2001;447-449.
6. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., Schäfer V., Brade V. New colorimetric method for in vitro susceptibility testing of B. burgdorferi against antimicrobial substances. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;27-32.
7. Hunfeld K.P., Kraicy P., Wichelhaus T.A., Schäfer V., Brade V. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against B. burgdorferi. Int. J. Antimicrob. Agents. 15:2000;11-17.
8. Williams J.D., Naber K.G., Bryskier A., et al. Classification of oral cephalosporins. Int. J. Antimicrob. Agents. 17:2001;443-450.
9. Preac-Mursic V., Wilske B., Schierz G. European B. burgdorferi isolated from humans and ticks: culture conditions and antimicrobial susceptibility. Zentralbl. Bakteriol. 263:1986;112-118.
10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 1999 Ninth Informational Supplement. NCCLS document M100-S9 [ISBN 1-56238-358-2]. NCCLS, Wayne, PA.
11. Odland B.A., Erwin M.E., Jones R.N. Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications. J. Clin. Microbiol. 38:2000;453-455.
12. Kraiczy P., Weigand J., Wichelhaus T.A., et al. In vitro activity of fluoroqinolones against the spirochete B. burgdorferi. Antimicrob. Agents Chemother. 45:2001;2486-2494.
13. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., Schäfer V., Brade V. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin, and fusidic acid against B. burgdorferi. Int. J. Antimicrob. Agents. 17:2001;203-208.
14. Hunfeld K.P., Kraiczy P., Kekoukh E., Schäfer V., Brade V. Standardised in vitro susceptibility testing of B. burgdorferi against well-known and newly developed antimicrobial agents - possible implications for new therapeutic approaches to Lyme disease. Int. J. Med. Microbiol. 291:2002;125-137.
15. Nadelman R.B., Luger S.W., Frank E. Comparison of cefuroxime-axetil and doxycyclin in the treatment of early Lyme disease. Ann. Intern. Med. 117:1992;273-280.
16. Hansen K., Hovemark A., Lebech A.M., et al. Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Dermatologica Venerologica. 72:1992;297-300.
17. Dever L.L., Jorgenson J.H., Barbour A.G. In vitro activity of vancomycin against the spirochete B. burgdorferi. Antimicrob. Agents Chemother. 37:1993;1115-1121.
18. Stephan C., Hunfeld K.P., Schönberg A., et al. Leptospirose-Erkrankungen nach einem Betriebsausflug. Dtsch. Med. Wochenschr. 125:2000;623-627.
19. Alexander A.D., Rule P.L. Penicillins, cephalosporins, and tetracyclins in treatment of hamsters with fatal leptospirosis. Antimicrob. Agents Chemother. 30:1986;835-839.
20. Brenot A., Trott D., Saint Girons I., Zuerner R. Penicillin-binding proteins in L. interrogans. Antimicrob. Agents Chemother. 45:2001;870-877.
21. Luft B.J., Volkman D.J., Halperin J.J., Dattwyler R.J. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann. N.Y. Acad. Sci. 539:1988;352-361.
22. Simon C., Stille W. Antibiotika Therapie in Klinik und Praxis. 10th ed. 2000;96-112 Schattauer Verlag, New York, Stuttgart.